Renalytix
Clinical Trials & Research
Renalytix is an AI-enabled in vitro diagnostics company focused on optimizing clinical management of kidney disease.
About Renalytix
Renalytix is focused on transforming kidney disease care with AI-powered solutions like KidneyIntelX, which provides data-driven insights for clinical teams.
Mission & Approach
Mission
“Dedicated to optimizing kidney disease management through precision based care intervention”
AI Approach
Machine learning algorithm for predictive analytics and risk stratification
Products & Solutions
kidneyintelX.dkd
FlagshipsoftwareFDA-approved blood test predicting progressive decline in kidney function in diabetic kidney disease patients
kidneyintelX.dkd is an FDA-authorized prognostic test that uses proprietary blood-based biomarkers (TNFR-1, TNFR-2, KIM-1), clinical features from EHRs, and machine learning to predict risk (low, moderate, high) for progressive decline in kidney function over 5 years in adult patients with type 2 diabetes and chronic kidney disease stages 1-3b. The test demonstrated 72% relative improvement in identifying high-risk patients compared to standard-of-care markers (eGFR and UACR) alone.
Customer Success Stories
University of Michigan
health system
Clinical validation and implementation of kidney disease risk stratification using molecular mechanisms and patient data
Clinical validation study cohort
other
HEDIS metric improvement in high-risk diabetic kidney disease patients
Mount Sinai
health system
Risk stratification for diabetic kidney disease patients to enable targeted treatment and specialist referrals
Singing River Health System
health system
Early identification and management of chronic kidney disease in diabetic patients
Hiring Activity
Product & Market
Product Stage
launchedPrimary Market
providersCompany Details
- Founded
- 2018
- Headquarters
- New York, NY, USA
- Employees
- 75
- Stage
- public
- Profile last updated
- June 22, 2026
Category
Clinical Trials & ResearchWork here?
Claim this listing to update company information and connect with our audience.
Claim This ListingSocial & Media
Follow on
X / Twitter
View Profile →Latest Updates
Commencement of trading on OTCQB in the United States
Commencement of trading on OTCQB in the United States Renalytix plc American Depository Shares (ADSs) begin trading on OTCQB Venture Market under symbol “RNLXY” effective from Market Open on October 8, 2024 LONDON and NEW YORK, Oct. 08, 2024 (GLOBE NEWSWIRE) — Renalytix plc (LSE: RENX) (OTCQB: RNLXY), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, annou
Renalytix™ and Carna Health Partner to Solve Kidney Disease Crisis: Bridging the Existing Gap Between Population Screening and Precision Intervention
Renalytix and Carna Health Partner to Solve Kidney Disease Crisis: Bridging the Existing Gap Between Population Screening and Precision Intervention The novel care model will integrate FDA-approved kidneyintelX.dkd and Carna Health’s digital health platform to identify at-risk patients, halt disease progression, and slash healthcare costs, significantly benefiting US health systems and providers NEW YORK and BOSTON , May 12, 2026 /PRNewswire/ — Renalytix PLC (LSE: RENX) (OTCQB: RNLXY ), a precis
Renalytix Announces Collaboration with Tempus to Advance Intelligent Risk Assessment in Diabetic Kidney Disease
Renalytix Announces Collaboration with Tempus to Advance Intelligent Risk Assessment in Diabetic Kidney Disease Definitive agreement to accelerate adoption of Renalytix’s FDA-approved, Medicare reimbursed kidneyintelX.dkd test to slow kidney disease progression and improve patient outcomes NEW YORK , Sept. 15, 2025 /PRNewswire/ — Renalytix plc (LSE: RENX) (OTCQB: RNLXY ), today announced an agreement with Tempus AI , Inc. (NASDAQ: TEM ) to make kidneyintelX.dkd prognostic blood testing more wide
Renalytix Submits Hearing Request to Nasdaq Hearings Panel in Regard to Staff Delisting Determination
Renalytix Submits Hearing Request to Nasdaq Hearings Panel in Regard to Staff Delisting Determination Throughout the hearings process and pending the Panel’s decision, the Company’s ADSs will continue trading on The Nasdaq Global Market under the symbol “RNLX” LONDON and NEW YORK, June 27, 2024 (GLOBE NEWSWIRE) — Renalytix plc (Nasdaq: RNLX) (LSE: RENX) announces that it has formally submitted a hearing request to the Nasdaq Hearings Panel (the “Panel”), which request has now stayed the suspen
Growing collaboration with NYKHM
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF THE MARKET ABUSE REGULATION (596/2014/EU) AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 (“MAR”). Renalytix plc (“Renalytix” or the “Company”) Growing collaboration with New York Kidney & Hypertension Medicine Renalytix collaborates with NYKHM to bring kidneyintelX.dkd testing to underserved communities in the Greater New York area, enabling access for over 2,000 patients LONDON and NEW YO
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as employee counts and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.